Drugs / BC8
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00589316 | Oct 2007 → Oct 2016 | acute myeloid leukemia, adult acute lymphoblastic leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome with excess blasts +2 | Fred Hutchinson Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT01678443 | Sep 1999 → Sep 2013 | Burkitt lymphoma, Hodgkins lymphoma, MALT lymphoma, T-cell large granular lymphocyte leukemia +19 | Fred Hutchinson Cancer Center | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00005940 | Oct 1999 → Jan 2006 | acute myeloid leukemia with 11q23 abnormalities, acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22), acute myeloid leukemia with t(8;21)(q22;q22) translocation | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BC8 | “Patients receive iodine I 131 monoclonal antibody BC8 intravenously (IV) on day -13.” NCT00005940 ↗2“iodine-131 (131I)-anti-CD45 antibody BC8 combined with nonmyeloablative conditioning” PMID 37939122 ↗ Jan 2024 |
| Known as | 131I-anti-CD45 | “iodine-131 (131I)-anti-CD45 antibody BC8 combined with nonmyeloablative conditioning” PMID 37939122 ↗ Jan 2024 |
| Modality | Monoclonal antibody | “iodine I 131 monoclonal antibody BC8” NCT00589316 ↗ |
| Route | Intravenous | “Patients receive iodine I 131 monoclonal antibody BC8 intravenously (IV) on day -13.” NCT00005940 ↗ |